Insider Transactions in Q4 2022 at Cti Biopharma Corp (CTIC)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
17,100
-14.76%
|
$102,600
$6.0 P/Share
|
|
Dec 30
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,100
+12.08%
|
$0
$0.84 P/Share
|
|
Dec 30
2022
|
Adam R Craig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,579
+5.09%
|
$7,895
$5.11 P/Share
|
|
Dec 30
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,847
-17.14%
|
$83,082
$6.0 P/Share
|
|
Dec 30
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,847
+12.97%
|
$0
$0.95 P/Share
|
|
Dec 30
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
214
+1.23%
|
$1,070
$5.11 P/Share
|
|
Dec 29
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
13,800
-33.12%
|
$82,800
$6.0 P/Share
|
|
Dec 29
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,800
+24.88%
|
$0
$0.84 P/Share
|
|
Dec 29
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,174
-43.79%
|
$79,044
$6.0 P/Share
|
|
Dec 29
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,174
+30.45%
|
$0
$0.95 P/Share
|
|
Nov 10
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
188,304
-21.85%
|
$1,129,824
$6.02 P/Share
|
|
Nov 10
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
188,304
+46.56%
|
$0
$0.84 P/Share
|
|
Nov 09
2022
|
Adam R Craig President and CEO |
SELL
Open market or private sale
|
Direct |
53,996
-26.21%
|
$323,976
$6.01 P/Share
|
|
Nov 09
2022
|
Adam R Craig President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
53,996
+39.75%
|
$0
$0.84 P/Share
|
|
Nov 08
2022
|
Michael A Metzger Director |
SELL
Open market or private sale
|
Direct |
91,500
-81.28%
|
$457,500
$5.63 P/Share
|
|
Nov 08
2022
|
Michael A Metzger Director |
BUY
Exercise of conversion of derivative security
|
Direct |
91,500
+45.39%
|
$0
$0.92 P/Share
|
|
Oct 04
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,109
-3.9%
|
$12,654
$6.26 P/Share
|
|
Oct 04
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,109
+3.68%
|
$0
$0.95 P/Share
|
|
Oct 03
2022
|
David Kirske EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
300
-1.74%
|
$1,800
$6.25 P/Share
|
|
Oct 03
2022
|
David Kirske EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+1.71%
|
$0
$0.95 P/Share
|